Treatment with any investigational agent within 4 weeks prior to cycle 1, day 1, or five drug half-lives (whichever is longer)Xx_NEWLINE_xXTreatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.Xx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days or five half-lives of the investigational agent, whichever is longer, prior to enrollmentXx_NEWLINE_xXExposure to an investigational product within 30 days or five half-lives (whichever is the longer) prior to randomizationXx_NEWLINE_xXParticipants may not be receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least two weeks or five half-lives, whichever is longer, before starting treatmentXx_NEWLINE_xXPatient who has participated in a prior investigational study within 30 days prior to treatment start or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXParticipation in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to first doseXx_NEWLINE_xXWithin two weeks (4 weeks for biologics) of first administration of BI 836858, or if the half-life of the previous product is known, within 5 times the half-life, whichever is longer.Xx_NEWLINE_xXPatients who are receiving any other investigational agents or have received other investigational agents within 2 weeks or 5 half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatmentXx_NEWLINE_xXParticipants may not have received treatment with another investigational drug or device within 28 days prior to day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to dosing, whichever may be longerXx_NEWLINE_xXInvestigational therapy (NOTE: or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer).Xx_NEWLINE_xXInvestigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this studyXx_NEWLINE_xXTreatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents within 2 weeks or 5 half-lives (whichever is longer and/or applicable) before first dose.Xx_NEWLINE_xXTreatment with any investigational drug or therapy within 2 weeks of study treatment, or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events (AEs) from previous treatment.Xx_NEWLINE_xXParticipation in a prior investigational study =< 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXAntitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half lives (whichever is longer) of day 1.Xx_NEWLINE_xXParticipation in any interventional study within 4 weeks of Cycle 1 Day 1 or 5 half-lives of the investigational agent(s) used in the interventional study prior to Cycle 1 Day 1 (whichever is longer).Xx_NEWLINE_xXReceived investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longerXx_NEWLINE_xXParticipation in any interventional study within 4 weeks or 5 half lives (whichever is longer) of Cycle 1 Day 1.Xx_NEWLINE_xXParticipation in a prior investigational study within 21 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is greater) prior to the initiation of study treatmentXx_NEWLINE_xXCurrent enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 28 days or 5 half lives (whichever is longer) of initiating study treatment.Xx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXParticipation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greaterXx_NEWLINE_xXPrevious chemotherapy and hormone therapy (excluding physiologic replacement) must be completed at least 4 weeks or 4 half-lives, whichever is longer, prior to administration of TAK-580Xx_NEWLINE_xXAdministration of investigational agents or investigational drugs </=4 weeks or less than (<)5 times the terminal half-life prior to study treatment start, whichever is longerXx_NEWLINE_xXHas received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)Xx_NEWLINE_xXParticipation in any other clinical study with investigational drug received within 28 days or 5 half lives (whichever is longer) before first doseXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization.Xx_NEWLINE_xXPreviously received investigational product in a clinical trial within 30 days or within 5 elimination half lives (whichever is longer) prior to the start of study therapy, or is planning to take part in another clinical trial while participating in this study.Xx_NEWLINE_xXParticipants who are currently receiving any other investigational agent or have received an investigational agent within 30 days or 5 half-lives prior to study entry, whichever is longer.Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to initiation of study treatmentXx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to treatment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXAny investigational treatment within 30 days or 5 half-lives, whichever is longer, of Day 1 of treatmentXx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXTreatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomizationXx_NEWLINE_xXReceipt of an investigational study drug for any indication within 30 days or 5 half-lives (whichever is longer) prior to day 1 of protocol therapyXx_NEWLINE_xXTreatment with any investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXSubject has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic (PK) half-lives (t1/2) of the treatment, whichever is longer, before the date of start of treatment.Xx_NEWLINE_xXParticipation in any interventional study within 4 weeks of randomization or 5 half-lives of the prior treatment agent (whichever is longer).Xx_NEWLINE_xX?28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational study drugs or devices.Xx_NEWLINE_xXTreatment with experimental therapy within 5 terminal half-lives (t1/2) or 4 weeks prior to enrollment, whichever is longer.Xx_NEWLINE_xXMonoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody.Xx_NEWLINE_xXOther IPs w/in 4 wks or 5 half-lives (whichever is longer) prior to study drugXx_NEWLINE_xXTreatment with any of the following; histamine receptor 2 inhibitors, proton pump inhibitors or antacids within 3 days or 5 half-lives of administration of BGB234, whichever is longer.Xx_NEWLINE_xXReceived IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer.Xx_NEWLINE_xXTreatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medicationXx_NEWLINE_xXTreatment with an EGFR TKI within 10 days or 5 half-lives of the first dose of study treatment, whichever is longerXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 2 months or within five half-lives of the compound, whichever is longerXx_NEWLINE_xXChemotherapy: within 21 days or 5 half-lives (whichever is longer) from enrolmentXx_NEWLINE_xXUse of an investigational product within 30 days or 5 half-lives, whichever is longer, preceding Study Day 0.Xx_NEWLINE_xXSubject has received an investigational drug in the 28 day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial.Xx_NEWLINE_xXMEDICATION-RELATED: Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer).Xx_NEWLINE_xXHas received prior anticancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer) before first dose of study treatment or not recovered (i.e., must be ? Grade 1 or at Baseline) from AEs due to previously administered agents.Xx_NEWLINE_xXAny other investigational agents within 2 weeks or =< 3 x half-lives (whichever is longer) before start of study therapyXx_NEWLINE_xXUse of other investigational drugs (drugs not marked for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administrationXx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisationXx_NEWLINE_xXInvestigational agent within 4 weeks prior to start of study treatment (or within five half-lives of the investigational product, whichever is longer).Xx_NEWLINE_xXPatients who have received targeted or investigational agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXSubjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.Xx_NEWLINE_xXAntitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, or investigational agent) within 14 days (Group 2 subjects) or 5 half-lives (whichever is longer: for Group 1 subjects) of day 1.Xx_NEWLINE_xXConcomitant use of another investigational agent and/or treatment with an investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXParticipants who are receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least one week or five half-lives, whichever is longer, before starting treatmentXx_NEWLINE_xXHave participated within the past 30 days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed.Xx_NEWLINE_xXReceived anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days before treatmentXx_NEWLINE_xXReceived active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to ScreeningXx_NEWLINE_xXMonoclonal antibody treatment and agents with known prolonged half-lives: < 3 halflives have elapsed or ? 28 days prior to screening, whichever is longer.Xx_NEWLINE_xXSubject has received therapy with a known moderate to potent CYP1A2 inhibitor within 14 days or 5 half-lives of first dose of study treatment (whichever is longer).Xx_NEWLINE_xXReceipt of an investigational study drug for any indication within 28 days or 5 half-lives (whichever is longer) prior to day 1 of protocol therapyXx_NEWLINE_xXSubject has received investigational therapy, with the exception of oncology drug trials, within 28 days or 5 half-lives, whichever is longer, prior to screening.Xx_NEWLINE_xXParticipant must not have been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, or is currently enrolled in another clinical study.Xx_NEWLINE_xXPatients must not have had investigational therapy administered =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this studyXx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to study treatment (or within five half lives of the investigational product, whichever is longer)Xx_NEWLINE_xXhave received any other investigational drug within 28 days (or 5 half-lives, if longer) prior to the start of study screening.Xx_NEWLINE_xXPatients receiving prohibited concomitant medications that cannot be discontinued or replaced by safe alternative medication at least 5 half-lives of the concomitant medication or 7 days, whichever is longer, prior to the start of pazopanib treatment.Xx_NEWLINE_xX(Atezolizumab-related exclusion) Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)Xx_NEWLINE_xXTreatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within 4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during study participationXx_NEWLINE_xXPatients may not be receiving any other investigational agents during protocol therapy, or up to 14 days or 5 half-lives (whichever is longer) prior to beginning protocol therapy; there should be a least a 1-week interval between last dose of endocrine therapy and protocol therapyXx_NEWLINE_xXParticipation in any other investigational drug study or had exposure to any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater)Xx_NEWLINE_xXTreatment with any investigational drug within 14 days prior to registration or within 5 half-lives of the investigational product, whichever is longer.Xx_NEWLINE_xXReceipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 3 half-lives, whichever is longer.Xx_NEWLINE_xXUse of other investigational agent at the time of screening, or within 30 days or five half-lives of screening 1, whichever is longerXx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXUse of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or at least 5 half-lives, whichever is longer, prior to entering the studyXx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)Xx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 21 days or 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXTreatment with any investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longerXx_NEWLINE_xXTreatment with anticancer therapy, including investigational therapy, or investigational procedures within 14 days or 5 x the half?life (whichever is longer) prior to the first dose of study drug. For prior biological therapies, eg, monoclonal antibodies with a half?life longer than 3 days, the interval must be at least 28 days prior to the first dose of study drug.Xx_NEWLINE_xXUse of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half?life (whichever is longer) prior to the first dose of study drug.Xx_NEWLINE_xXPatients who are receiving any other investigational agents concurrently or have received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatmentXx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXParticipation in a prior investigational interventional study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXTreatment with any investigational products, radiation therapy, surgery, tumor embolization, chemotherapy or immunotherapy within 21 days before the first dose of the study drug; for biologic or hormonal therapy treatment within 14 days or five half-lives of a drug (whichever is longer) before the first dose of study drugXx_NEWLINE_xXAny anti-cancer therapy (eg, chemotherapy, biologics, radiotherapy, or hormonal treatment) within 4 weeks or at least 5 half-lives (whichever is longer) of study drug administrationXx_NEWLINE_xXParticipation in another interventional study requiring investigational treatment intake within 2 weeks or at least 5 half-lives (whichever is longer) prior to first dose of S64315 (participation in non-interventional registries or epidemiological studies is allowed).Xx_NEWLINE_xXReceived investigational products within 14 days or 5 half-lives of the first study dosing day, whichever is longerXx_NEWLINE_xXParticipation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greaterXx_NEWLINE_xXHas received an investigational drug, investigational vaccine, or has used an investigational medical device within 4 weeks or 4 half-lives, whichever is longer, before cycle 1, day 1 of study therapyXx_NEWLINE_xXAny prior (neo) adjuvant anti-cancer therapy or prior chemotherapy for metastatic disease must be stopped at least 5 half-lives or 7 days, whichever is longer, before study inclusion.Xx_NEWLINE_xXOral targeted therapy within five days or five half-lives, whichever is longer, prior to initiating protocol therapy treatmentXx_NEWLINE_xXPrior chemotherapy must have been completed at least 4 weeks or at least 5 half-lives (whichever is longer) before study drug administration, and all adverse events have either returned to baseline or stabilized; for EGFR and ALK tyrosine kinase inhibitor (TKI) 5 half-lives wash out is requiredXx_NEWLINE_xXTreatment with any investigational medicinal product (IMP) within 4 weeks prior to initiation of 1st infusion of study drug, or treatment with a drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, of the 1st infusion of study drug.Xx_NEWLINE_xXMedications known to cause QTc interval prolongation (within 7 days OR five half-lives prior to Study Day 1, whichever is longer).Xx_NEWLINE_xXParticipation in a clinical study within 28 days or 5 half-lives of the drug, whichever is longer.Xx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXNote: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamideXx_NEWLINE_xXPrior therapy with investigational drugs within 28 days or at least 5 half-lives (whichever is longer) before study administrationXx_NEWLINE_xXDONOR: Received any investigational agent within 30 days and/or 5 half-lives (of the other investigational agent), whichever is longer, of receiving BL-8040Xx_NEWLINE_xXPatients who are receiving any other investigational agents concurrently or have received investigational agents within 2 weeks or 5 half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatmentXx_NEWLINE_xXTreatment with systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any investigational therapy within 4 weeks (< 6 weeks for nitrosourea or mitomycin-C, antibodies except for trastuzumab) or within 5-half lives of the investigational therapy prior to starting study treatment, whichever is longerXx_NEWLINE_xXPatient is currently participating or has participated in a study with an investigational compound or device within 30 days of study day 1 or within 5 half-lives of the investigational product, whichever is longer, with the exception of a prior cyclin dependent kinase (CDK) 4/6 inhibitorXx_NEWLINE_xXParticipation in a prior investigational therapeutic study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXApplicable to Cohorts 1-4 and Cohort 6 only: Previous anti-cancer and investigational agents within 4 weeks or ? 5 x half-life of the agent (whichever is longer) before first doseXx_NEWLINE_xXExposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisationXx_NEWLINE_xXHas participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostatXx_NEWLINE_xXHave used any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drugXx_NEWLINE_xXTreatment with an investigational agent within 28 days of study entry, or 3 half-lives, whichever is longerXx_NEWLINE_xXAspirin within 7 days, or 5 half-lives, whichever is longerXx_NEWLINE_xXAn antiplatelet/anticoagulant drug or a herbal supplement that affects platelet function within 7 days, or 5 half-lives, whichever is longerXx_NEWLINE_xXReceived targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXUse of any investigational drug, other than eltrombopag or romiplostim, ? 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first dose of RTX-100Xx_NEWLINE_xXAny investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of SB-485232Xx_NEWLINE_xXAdministration of any non-oncologic investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the first dose of pazopanibXx_NEWLINE_xXMonoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody.Xx_NEWLINE_xXThe subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXUse of an investigational drug outside this study within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.Xx_NEWLINE_xXPatients who have discontinued any of these medications must have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of dinaciclibXx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study; administration of any non-oncologic investigational drug within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatmentXx_NEWLINE_xXTreatment with an EGFR TKI (i.e. erlotinib, gefitinib or afatinib) within 8 days or approximately 5 x half-life, whichever is longer, of the first dose of study treatmentXx_NEWLINE_xXSubject has received investigational therapy within 28 days or 5 half lives, whichever is longer, prior to screeningXx_NEWLINE_xXReceived an investigational agent within 5 half-lives or 14 days, whichever is longer, prior to receiving the first dose of study drugXx_NEWLINE_xXChemotherapy within 21 days (6 weeks for nitrosoureas) or at least 5 half-lives (whichever is longer) prior to study treatment.Xx_NEWLINE_xXTreatment with another investigational drug, biological agent, or device within 6 months of screening, or 5 half-lives of the study agent, whichever is longer.Xx_NEWLINE_xXTreatment with any local or systemic anti-neoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, up to a maximum wash-out period of 28 days prior to the initiation of study drug administrationXx_NEWLINE_xXChemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents within 5 half-lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study drug on Day 1 or have not recovered from the side effects of such therapy;Xx_NEWLINE_xXUse of an investigational product (IP) within 30 days or 5 half-lives, whichever is longer, preceding Study Day 0.Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomizationXx_NEWLINE_xXUse of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.Xx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer).Xx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXAny investigational agent within 14 days or 5 half-lives prior to enrollment, whichever is longer.Xx_NEWLINE_xXparticipants who are currently receiving any other investigational agent or have received an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to study entryXx_NEWLINE_xXTyrosine kinase inhibitors within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment.Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to Cycle 1, Day 1Xx_NEWLINE_xXThe subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXUse of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study drugXx_NEWLINE_xXDOSE ESCALATION COHORT: Participation in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) before first doseXx_NEWLINE_xXDOSE EXPANSION COHORT: Participation in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) before first doseXx_NEWLINE_xXParticipation in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment (6 weeks for nitrosoureas or mitomycin C)Xx_NEWLINE_xXTreatment with any investigational agent within 30 days (or 5 serum half-lives of the investigational drug, whichever is longer) of enrollmentXx_NEWLINE_xXPatients who have received investigational agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXNo prior treatment with a small molecule kinase inhibitor or a hormonal therapy within 14 days or 5 half-lives (whichever is longer)Xx_NEWLINE_xXChemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy\n             will not be allowed within either 30 days, or 5 half lives (whichever is longer)\n             prior to study drug administration.Xx_NEWLINE_xXAt least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibodyXx_NEWLINE_xXOther investigational study agent (any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric) (At least 30 days or five half-lives, whichever is longer, since last dose prior to the first dose of tazemetostat)Xx_NEWLINE_xXHas participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostatXx_NEWLINE_xXUse of any investigational drug within 28 days or 5 half-lives, whichever is longer, preceding enrollmentXx_NEWLINE_xXSubjects who participated in any other study in which receipt of an investigational study drug or device occurred within 2 weeks or 5 half-lives (whichever is longer) prior to first dose.Xx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the studyXx_NEWLINE_xXHas received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)Xx_NEWLINE_xXHas received investigational agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1Xx_NEWLINE_xXAntibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 half-lives of the respected antibody, whichever is longerXx_NEWLINE_xXPatient has participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXAdministration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatmentXx_NEWLINE_xXAdministration of any non-oncologic investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the first dose of pazopanibXx_NEWLINE_xXPrior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXUse of any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatmentXx_NEWLINE_xXTreatment with any investigational product within < 4 half-lives for each individual investigational product OR 28 days prior to randomizationXx_NEWLINE_xXParticipation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatmentXx_NEWLINE_xXAny investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatmentXx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or =< 5 half-lives of the investigational product, whichever is longerXx_NEWLINE_xXHas received investigational agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin 2 [IL-2]) within 6 weeks or five drug elimination half-lives prior to Day 1 of Cycle 1, whichever is longerXx_NEWLINE_xXExposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisationXx_NEWLINE_xXParticipation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.Xx_NEWLINE_xXUse or expected use during the study of any prohibited medications, including potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half lives (whichever is longer) before the first dose of study drug.Xx_NEWLINE_xXInvestigational drug; 30 days or five half-lives, whichever is longer, from last doseXx_NEWLINE_xXTyrosine kinase inhibitor (TKI) therapy within 2 weeks or at least 5 half-lives (whichever is longer) prior to planned start of study treatment.Xx_NEWLINE_xXUse of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.Xx_NEWLINE_xXExposure to another investigational drug within 42 days of first dosing visit, or 5 half-lives of the study product (whichever is longer)Xx_NEWLINE_xXParticipation in any other study in which receipt of an investigational study drug or device occurred within 2 weeks or 5 half-lives (whichever is longer) before first dose.Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is longer) prior to initiation of study treatmentXx_NEWLINE_xXHave received oral anti-cancer therapy with oral tyrosine kinase inhibitors within 14 days or 5 half-lives, whichever is longer.Xx_NEWLINE_xXParticipation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to enrollmentXx_NEWLINE_xXAre currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x the half-life of the investigational drug/device, whichever is longer) preceding informed consentXx_NEWLINE_xXAny investigational drug therapy less than 28 days or 3 half-lives (whichever is longer) prior to first dose of study treatmentXx_NEWLINE_xXTreatment with an EGFR TKI (e.g., erlotinib or gefitinib) within 8 days or approximately 5 x half-life, whichever is the longer, of the first dose of study treatment.Xx_NEWLINE_xXPatients that received glucocorticoid replacement therapy post-operatively must have discontinued such therapy for at least one week, or 5 half-lives, whichever is longer, prior to screening.Xx_NEWLINE_xXUse of other investigational drugs at the time of enrollment, or within 30 days or 5 half lives at the time of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.Xx_NEWLINE_xXHas received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a maximum of 4 days) before treatment. A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is provided in the Site Investigational Product Procedures Manual (IPPM).Xx_NEWLINE_xXHas received prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer) before first dose of trial drug or not recovered (? Grade 1 or at baseline) from AEs due to previously administered agents (Parts 1A and 1B)Xx_NEWLINE_xXAny anti-cancer therapy (e.g., chemotherapy, biologics, radiotherapy, or hormonal treatment) within 4 weeks or at least 5 half-lives (whichever is longer) of study drug administrationXx_NEWLINE_xXThe subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXConcomitant use of another investigational agent and/or treatment with an investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXSubject has received an investigational drug in the 28 day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial.Xx_NEWLINE_xXParticipation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.Xx_NEWLINE_xXAny investigational agent =< 28 days or 5 half-lives prior to randomization (whichever is longer)Xx_NEWLINE_xXFOLLOWING ARE medication-related exclusion criteria: \r\n*Treatment with systemic immunostimulatory agents (including but not limited to interferon-a [IFN-a], interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to the start of chemoradiation; treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)Xx_NEWLINE_xXPatients should be off radiation therapy, chemotherapy, investigational agents, hormonal therapy, or immunotherapy for 4 weeks (or 5 half-lives of the therapy, whichever is longer) prior to first dose in the study, and off bevacizumab 6 weeksXx_NEWLINE_xXUse of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening, andXx_NEWLINE_xXParticipation in any other clinical studies involving investigational drug(s) within 14 days or within 3 half-lives of drug levels in blood (whichever is longer) prior to the first dose of bosutinib.Xx_NEWLINE_xXAdministration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatmentXx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical studyXx_NEWLINE_xXPatients who have received targeted or investigational agents prior to registration within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXAdministration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.Xx_NEWLINE_xXBiologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy with a biologic agentXx_NEWLINE_xXSubject has received an investigational agent within 4 weeks or 5 half lives whichever is longer prior to Day 1.Xx_NEWLINE_xXAnti-myeloma therapy, including radiotherapy, within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) prior to day 1 and who have not recovered from side effects (to =< grade 1) of those therapiesXx_NEWLINE_xXAny prior (neo) adjuvant anti-cancer therapy must be stopped at least 5 half-lives or 7 days, whichever is longer, before randomizationXx_NEWLINE_xXExposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to start of the current study drug.Xx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the studyXx_NEWLINE_xXAdministration of any non-oncologic investigational drug within 30 days or 5 half lives whichever is longer prior to receiving the firstXx_NEWLINE_xXParticipation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greaterXx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXTreatment with experimental non-Food and Drug Administration (FDA) approved therapy within 5 terminal half-lives or 4 weeks prior to enrollment, whichever is longerXx_NEWLINE_xXAntineoplastic therapy with biological agents within 2 weeks before day 1 or within 5 drug half-lives (t½) prior to first dose, whichever time period is longerXx_NEWLINE_xXTreatment with another investigational drug during the study or within 3 weeks before day 1 or within 5 drug half-live (t½) prior to first dose, whichever time period is longerXx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications listed for at least 14 days or five half-lives of a drug (whichever is longer) prior to registration and for the duration of the studyXx_NEWLINE_xXTreatment with any of the following anti-cancer or non-oncologic investigational therapies: \r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to registration\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or 2.5 half-lives of a drug (whichever is longer) prior to registration\r\n* Non-oncologic investigational products within 30 days or 5 half-lives prior to registration, whichever is longerXx_NEWLINE_xXThe participant has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical studyXx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXPatients may have received prior VHL-related systemic therapy, provided not within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanibXx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications list for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the studyXx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives (calculated by multiplying the reported terminal half-life by 5) or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical studyXx_NEWLINE_xXAdministration of any non-oncologic investigational drug within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatmentXx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited fruit (or its juices) and prohibited medications for at least 14 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the studyXx_NEWLINE_xXTreatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medicationXx_NEWLINE_xXUse of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drugXx_NEWLINE_xXEXPANSION COHORT ONLY: Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drugXx_NEWLINE_xXPatients who have received another investigational product within the longer of 14 days or 5 half-lives of the previous productXx_NEWLINE_xXThe participant has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.Xx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)Xx_NEWLINE_xXFor patients previously treated with chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent, discontinuation must have occurred ?2 weeks, or after at least 4 half-lives, whichever is longer, prior to study drug administration. For enzalutamide and apalutamide, the washout period will be at least 3 weeks prior to start of study drug with no evidence of an anti-androgen withdrawal response (i.e., no decline in serum PSA).Xx_NEWLINE_xXExposure to any investigational product (IP) within 30 days or 5 half-lives (whichever is longer) prior to start of study treatment;Xx_NEWLINE_xXParticipation in any other clinical study with a potentially therapeutic agent or receipt of another investigational product within 21 days or 5 plasma half-lives, whichever is longer, prior to first day of drug administration (Day 1).Xx_NEWLINE_xXCurrent treatment with an investigational study drug or immunological-based agent for any reason, or receipt of anticancer medication within 21 days or 5 half-lives (whichever is longer) before first dose.Xx_NEWLINE_xXRadiation therapy within 28 days or 5 half-lives prior to C1D1, whichever is longerXx_NEWLINE_xXInvestigational drug use within 28 days or 5 half-lives, whichever is longer, prior to C1D1Xx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXSubject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.Xx_NEWLINE_xXNon-cytotoxic small molecule therapeutics: ?5 half-lives or ?2 weeks (whichever is longer)Xx_NEWLINE_xXUse of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or even longer if required by local regulations. Concomitant investigational treatment, including treatment in the context of a clinical trial with marketed drugs (off-label) may be acceptable but requires approval by the sponsor on the case by case basis.Xx_NEWLINE_xXTreatment with investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five half lives of the investigational product, whichever is longer)Xx_NEWLINE_xXInvestigational drug use within 14 days (or 5 half-lives, whichever is longer) of the first dose of PLX73086.Xx_NEWLINE_xXStrong CYP3A4 inhibitors or inducers as well as inhibitors of breast cancer resistance protein (BCRP) within 14 days or 5 drug half-lives, whichever is longer, before start of study drug.Xx_NEWLINE_xXReceived an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug.Xx_NEWLINE_xXReceived any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug EXCEPT steroids at ? 10 mg prednisone daily (or equivalent).Xx_NEWLINE_xXSubjects who had received investigational drug treatment, including BAY1143269 and docetaxel, outside of this study within 4 weeks before the first dose of study drug, or for small molecules within the 5 half-lives of the agent before the first dose of study drug, whichever is longerXx_NEWLINE_xXAdministration of other investigational agents for the treatment of AML/MDS within 21 days (or 5 times the terminal half-life of the investigational treatment whichever is longer) of the start of this trial and throughout the duration of this trialXx_NEWLINE_xXTreatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)Xx_NEWLINE_xXParticipated in any interventional study within 4 weeks of randomization or 5 half lives (whichever is longer).Xx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug, whichever is longer, prior to the first dose of study drug and for the duration of the study treatment.Xx_NEWLINE_xXAdministration of any non-oncologic investigational drug within 30 days or five half-lives (whichever is longer) prior to the protocol-mandated 4-week drug holiday.Xx_NEWLINE_xXPrior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, or before the first dose of study treatmentXx_NEWLINE_xXThe subject has received prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXThe subject has received prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participateXx_NEWLINE_xXStrong CYP3A4 inhibitors or inducers within 14 days or 5 drug half-lives of the agent, whichever is longer, of study drug initiation or the need to continue these drugs during this study.Xx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXPatient has participated in any interventional clinical trial for an aGVHD therapeutic agent or for an immunomodulatory drug, within the past 30 days or within 5 half-lives of the investigational medicinal product (IMP), whichever is the greater.Xx_NEWLINE_xX< 5 half-lives or 14 days, whichever is longer, for any investigational agent (for any indication)Xx_NEWLINE_xXWithin two weeks (4 weeks for biologics or 5 half-lives, whichever is longer) of first administration of BI 836858; orXx_NEWLINE_xXParticipation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this studyXx_NEWLINE_xXPatients who have received other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study enrollmentXx_NEWLINE_xXChemotherapy, hormonal therapy or radiation therapy within the past 3 weeks, antibody/biologic therapy within 5 half-lives or within the past 4 weeks (whichever is longer)Xx_NEWLINE_xXPrior therapy with any biologic chemotherapeutic or investigational drug within 5 half-lives or 3 weeks, whichever is longer prior to the first dose of TKM 080301.Xx_NEWLINE_xXAt least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibodyXx_NEWLINE_xXWashout from prior chemotherapy of at least 2 weeks or 1 elimination half-life, whichever is longer, prior to C1D1Xx_NEWLINE_xXAny investigational or experimental therapy or procedure or participation in any interventional trial within 4 weeks or 5 half-lives (whichever is longer) prior to start of study treatmentXx_NEWLINE_xXUse of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longerXx_NEWLINE_xXSubject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to the initiation of screening.Xx_NEWLINE_xXPatients who have taken part in an experimental drug study within 4 weeks or 5 half-lives (whichever is longer) of initiating treatment with LDE225Xx_NEWLINE_xXParticipated in a therapeutic clinical study within 3 weeks (2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other therapeutic investigational procedures.Xx_NEWLINE_xXReceived investigational agents within 14 days or 5 half-lives of the first study dosing day, whichever is longer.Xx_NEWLINE_xXTreatment with an investigational drug within 30 days or 5 half lives, whichever is longer, preceding the first dose of study medication.Xx_NEWLINE_xXFor Arms A and C: Treatment with any FGFR inhibitor. For Arm B: Treatment with any anti-cancer therapy (for biological anti-cancer therapies see criteria below) during the preceding 4 weeks or within 4 half-lives of the therapy, whichever is longer.Xx_NEWLINE_xXThe subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentXx_NEWLINE_xXReceipt of any investigational product within 28 days prior to study drug administration or 5 half-lives, whichever is longer.Xx_NEWLINE_xXAdministration of an investigational study treatment within 28 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment(s) in this studyXx_NEWLINE_xXPatients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapiesXx_NEWLINE_xXUse of any investigational drug within 28 days or 5 half-lives, whichever is longer, preceding enrollment; for the purposes of this study, bevacizumab will not be considered investigational therapyXx_NEWLINE_xXThe subject has received an investigational product within the following time period prior to the first dosing day in the current study: 28 days or 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is warranted by the data).Xx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 Weeks prior to first study treatment dose, whichever is longer, or participation in any other interventional clinical study.Xx_NEWLINE_xXTherapeutic monoclonal antibody use within the longer of 6 weeks or 5 plasma half-livesXx_NEWLINE_xXUnable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of study treatment.Xx_NEWLINE_xXUse of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatmentXx_NEWLINE_xXUsed an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.Xx_NEWLINE_xXUsed an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of protocol treatment;Xx_NEWLINE_xXTreatment with any investigational drug within 2 weeks or 3 half lives (whichever is longer) of the first dose of elotuzumab.Xx_NEWLINE_xXTreatment with any other anti-cancer therapies (e.g. other radiation, surgery or tumor embolization) within the last 14 days prior to first dose of study drug; or chemotherapy, immunotherapy, biologic therapy, investigational or hormonal therapy within 14-days (or 5 half-lives of a drug whichever is longer) prior to the first dose of the study drug pazopanibXx_NEWLINE_xXParticipated in a prior anticancer investigational study =< 30 days prior to enrollment, or =< 5 half-lives of the anticancer investigational product, whichever is longer (treatment with somatostatin analogue [SSTa] while on dovitinib is allowed provided patient’s tumor has progressed on therapy prior to initiating dovitinib treatment)Xx_NEWLINE_xXHave stopped previous anticancer therapy for at least 2 weeks or 5 half-lives (whichever is longer) if the immediate prior regimen included only chemotherapy; or 4 weeks or 5 half-lives (whichever is longer) from any therapy with therapeutic biologics and from any type of investigational therapy.Xx_NEWLINE_xXTreatment within 14 days or five half lives prior to enrollment whichever is longer with any type of systemic anticancer-therapy or any investigational drugXx_NEWLINE_xXTreatment within 14 days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer.Xx_NEWLINE_xXPatients who have taken any medication classified as a strong CYP3A4 inducer within one week of study day 1 or 5 half-lives (whichever is longer) or use of a strong or moderate CYP3A4 inhibitor within one week of study day 1 or 5 half-lives (whichever is longer)Xx_NEWLINE_xXPatient must not have been dosed with test drug or blinded study drug in another investigational study within 30 days or 5 half-lives of the biologic activity of the test drug, whichever is longer, before the time of first study doseXx_NEWLINE_xXTreatment with systemic immunostimulatory agents within 6 weeks or five half-lives of the drug, whichever is longer, prior to screeningXx_NEWLINE_xXTreatment with any of the following: histamine receptor two inhibitors, protocol pump inhibitors or antacids within three days or five half-lives, whichever is longerXx_NEWLINE_xXTreatment with another investigational drug or device within 28 days prior to day 1, or if the half-life of the previous product is known, within 5 times the half-life of the investigational drug prior to dosing, whichever is longerXx_NEWLINE_xXTreatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medicationXx_NEWLINE_xXPatients who have taken part in an experimental drug study within 4 weeks or 5 half-lives, whichever is longer, of initiating treatment with LDE225Xx_NEWLINE_xXTreatment with any non-Food and Drug Administration (FDA) approved agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of study enrollmentXx_NEWLINE_xXGerman centers only: Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or participation in any other interventional clinical study.Xx_NEWLINE_xXPatient must not have been dosed with test drug or blinded study drug in another investigational study within 30 days or 5 half-lives of the biologic activity of the test drug, whichever is longer, before the time of first study doseXx_NEWLINE_xXParticipation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this studyXx_NEWLINE_xXBiologic or other approved molecular targeted small molecule inhibitors should be washed out 1 week or 5 half-lives (whichever is longer) before apheresis and must be completed at least 1 week or 5 half-lives (whichever is longer) prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXExposure to investigational drug (including investigational vaccines) or invasive investigational medical device for any indication within 4 weeks or 5 half-lives, whichever is longer, before Cycle 1, Day 1Xx_NEWLINE_xXHas been treated with an investigational agent within 30 days or six half-lives of its biologic activity whichever is longer, before the start of study. (Patients may not be concurrently enrolled on another trial or concurrently treated with another investigational agent)Xx_NEWLINE_xXUse of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding enrollmentXx_NEWLINE_xXPatient must not be unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the studyXx_NEWLINE_xXChemotherapy or targeted therapy within 14 days or 5 half-lives (whichever is longer) prior to the start of study treatmentXx_NEWLINE_xXParticipation in a therapeutic clinical study within 3 weeks before study drug treatment (for small-molecule targeted agents, this non-participation period is 2 weeks or 5 half-lives, whichever is longer), or current participation in other investigational procedures.Xx_NEWLINE_xXPrior anti-cancer therapy within 28 days or 5 times the half-life whichever is longerXx_NEWLINE_xXReceived IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longerXx_NEWLINE_xX